ArticleFrontiers in oncology2026
Predicting postoperative recurrence and survival in malignant ovarian germ cell tumors: a single-center retrospective cohort study and nomogram development.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant ovarian germ cell tumors (MOGCTs) are associated with a relatively good prognosis when diagnosed early and treated appropriately. However, disease recurrence significantly worsens outcomes. Therefore, identifying risk factors for recurrence is crucial for improving patient prognosis. The role of carcinoembryonic antigen (CEA) in MOGCTs remains unclear, and this study aimed to evaluate its prognostic value. Methods: This single-center retrospective study included 123 MOGCT patients treated between January 2012 and December 2024. Data on clinical characteristics, serological markers (including CEA), surgical details, and follow-up outcomes were collected. Cox proportional hazards regression analyzed risk factors for postoperative recurrence and all-cause mortality. Kaplan-Meier curves evaluated progression-free survival (PFS) and overall survival (OS). Nomograms were developed to predict the probabilities of recurrence and mortality. Results: Multivariate analysis identified that advanced International Federation of Gynecology and Obstetrics (FIGO) stage (II-IV) (HR = 5.299, P = 0.004), presence of metastasis (HR = 3.364, P = 0.015), and elevated preoperative CEA (HR = 4.237, P = 0.019) as independent risk factors for postoperative recurrence; For mortality, stage II-IV disease (HR = 5.398, P = 0.044) and elevated preoperative CEA (HR = 5.779, P = 0.012) were identified as risk factors. Predictive nomograms for recurrence and OS were successfully established. Conclusions: Tumor stage, metastasis status, and preoperative CEA level are predictive of postoperative recurrence in MOGCTs, while tumor stage and preoperative CEA level also predict postoperative OS. These findings may facilitate the identification of high-risk patients for early intervention. Further research is needed to explore the relationship between dynamic changes in CEA and the risk of recurrence. Although the routine application of CEA in MOGCTs requires more evidence, this study suggests it may serve as a potential supplementary prognostic indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.